Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Inclusion Criteria: * Age ≥18 years (≥ 20 years in Japan; ≥ 19 years in South Korea) * Easter Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate bone marrow function, renal and liver functions Phase 1b * Histological or Cytological diagnosis of advanced solid tumor with clinical evidence of response to anti-PD-1 or PD-L1 agent * Participant must have received at least 1 prior line of therapy for recurrent or metastatic disease, and must have progressed/relapsed, be refractory, or intolerant to standard therapy approved for the specific tumor type Phase 2 * Participants must have a documented diagnosis of stage III where participants are not candidates for surgical resection or definitive chemoradiation, or stage IV NSCLC * EGFR mutation, BRAF mutation, and ALK or ROS1 translocation/rearrangement are not permitted * Participants whose tumor is known to be PD-L1 positive (Tumor Proportion Score \[TPS\] ≥1%) or unknown are eligible * Up to 1 line of prior therapy in advanced or metastatic disease settings allowed * Participant should not have received prior treatment with anti PD-1/PD-L1 drugs * At least one measurable lesion as defined by RECIST version 1.1 Exclusion Criteria: * Participants with known symptomatic brain metastases requiring steroids * Participants with Interstitial Lung Disease history or complication * Q-T interval corrected for heart rate QTc \> 450 msec for male participants or QTc \> 470 msec for female participants or QTc \> 480 msec…